ClinicalTrials.gg
TerminatedNCT01392495Updated Aug 10, 2015Results posted

Extension to CQTI571A2102 to Evaluate Long-term Safety, Tolerability and Efficacy of Imatinib in Severe Pulmonary Arterial Hypertension (PAH)

A Phase 3 interventional study of Imatinib in Pulmonary Arterial Hypertension, sponsored by Novartis Pharmaceuticals. Terminated at 7 sites in 7 countries. Per ClinicalTrials.gov, last updated 2015-08-10.

Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 3, Interventional, and Treatment

Why this study was terminated
Novartis discontinued the development of imatinib in PAH due to requirement of regulatory authorities for additional data to secure marketing approval in PAH.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
17
Allocation
Non-randomized
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 12 studies in Pulmonary Arterial Hypertension by Novartis — 1 open to participants now, 1 under way, none of them phase 3. Pulmonary Arterial Hypertension · Novartis.

Enrollment
9th of 12
17 · median 27
Started
2011
with 1 other
Phase 3
5 of 12
none open now
Registered
6th of 12
by date

Among the 12 studies in Pulmonary Arterial Hypertension by Novartis, this one is the 9th largest by enrollment, is one of 2 that started in 2011, is one of 5 in phase 3, and was the 6th registered.

Pulmonary Arterial Hypertension

700 studies on the registry are indexed under Pulmonary Arterial Hypertension; 141 are open to participants now.

Browse Pulmonary Arterial Hypertension studies →

Open to participants now

1 of the 12 studies in Pulmonary Arterial Hypertension by Novartis is open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

Who these studies take

Of the 90 Pulmonary Arterial Hypertension studies recruiting now, 51 (57%) set no upper age limit and 24 (27%) stop at 75 or younger; 18 take children under 18; 11 take healthy volunteers.

This study: all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 12 studies in Pulmonary Arterial Hypertension by Novartis, or all of them as a file.
02

Study summary

This study was an extension to study CQTI571A2102 and was to evaluate the long-term safety, tolerability and efficacy of QTI571 (imatinib) in severe pulmonary arterial hypertension patients.

03

Conditions studied

  • Pulmonary Arterial Hypertension

Keywords

  • Pulmonary arterial hypertension
  • imatinib
  • 6MWD
04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients who completed in CQTI571A2102 clinical trial including all Study Completion assessments at the end of study visit met the eligibility criteria for that study and did not meet withdrawal criteria for safety reasons during study conduct

Exclusion criteria

Exclusion Criteria:

  • Patients with (LVEF) \< 45%
  • Patients with thrombocytopenia, count \< 50 x109/L (50 x 103/µL).
  • Patients with uncontrolled systemic arterial hypertension, systolic pressure > 160 mmHg or diastolic pressure > 90 mmHg.
  • Patients with a > 450 ms for males and > 470 ms for females in the absence of right bundle branch block.

Other protocol-defined inclusion/exclusion criteria may apply

Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
17 participants (actual)

Study arms

  • Experimental
    QTI571

    Participants received 200 mg or 400 mg every day (qd) based on their highest tolerated dose in CQTI571A2102 (NCT01392469).

    Drug: Imatinib

Interventions

06

What researchers measure

Primary outcomes

  1. Number of Patients With Adverse Events, Serious Adverse Events and Deaths

    Adverse event monitoring was conducted throughout the trial.

    Time frame: 144 weeks

Secondary outcomes

  1. Change From Baseline in the Six Minute Walk Distance (6MWD)

    Time frame: baseline, 144 weeks

  2. Time to Clinical Worsening (TTCW) Endpoints

    Time frame: 144 weeks

  3. Medical Resource Utilization

    Time frame: 144 weeks

07

Results

Posted Jul 13, 2015

Participant flow

Participant flow — Overall Study
MilestoneQTI571
Started17
Received 200 mg4
Received 400 mg13
Completed1
Not completed16
Withdrew: Death3
Withdrew: Administrative problems8
Withdrew: Withdrawal by subject2
Withdrew: Adverse event3

Outcome measures

PrimaryNumber of Patients With Adverse Events, Serious Adverse Events and Deaths

Adverse event monitoring was conducted throughout the trial.

Time frame:
144 weeks
Reported as:
Number · Participants
Number of Patients With Adverse Events, Serious Adverse Events and Deaths
ParticipantsQTI571 200 mgQTI571 400 mg
Adverse Events (serious and non-serious)413
Serious Adverse Events45
Deaths21
SecondaryChange From Baseline in the Six Minute Walk Distance (6MWD)
Time frame:
baseline, 144 weeks

No measurements were reported for this outcome.

SecondaryTime to Clinical Worsening (TTCW) Endpoints
Time frame:
144 weeks

No measurements were reported for this outcome.

SecondaryMedical Resource Utilization
Time frame:
144 weeks

No measurements were reported for this outcome.

Adverse events

Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
QTI571 200mg—4/4 (100%)4/4 (100%)
QTI571 400mg—5/13 (38.5%)13/13 (100%)
Most frequent serious events
Showing 10 of 21
Most frequent serious events
EventQTI571 200mgQTI571 400mg
Iron deficiency anaemiaBlood and lymphatic system disorders1/40/13
Right ventricular failureCardiac disorders1/40/13
Gastrointestinal haemorrhageGastrointestinal disorders1/41/13
Inguinal herniaGastrointestinal disorders1/40/13
BacteraemiaInfections and infestations1/40/13
PeritonitisInfections and infestations1/40/13
Septic shockInfections and infestations1/40/13
Back painMusculoskeletal and connective tissue disorders1/41/13
Adenocarcinoma of colonNeoplasms benign, malignant and unspecified (incl cysts and polyps)1/40/13
CatatoniaPsychiatric disorders1/40/13
Most frequent other events
Showing 10 of 68
Most frequent other events
EventQTI571 200mgQTI571 400mg
AnaemiaBlood and lymphatic system disorders2/43/13
DiarrhoeaGastrointestinal disorders0/46/13
NasopharyngitisInfections and infestations0/46/13
VomitingGastrointestinal disorders0/44/13
LeukopeniaBlood and lymphatic system disorders1/40/13
ThrombocytopeniaBlood and lymphatic system disorders1/40/13
Abdominal discomfortGastrointestinal disorders1/41/13
GastritisGastrointestinal disorders1/40/13
Gastrooesophageal reflux diseaseGastrointestinal disorders1/40/13
ToothacheGastrointestinal disorders1/41/13

Baseline characteristics

Age, Continuous
Age, Continuous(Years)QTI571
Mean53.5 ± 14.3
Sex: Female, Male
Sex: Female, Male(Participants)QTI571
Female11
Male6
08

Study locations

7 sites
  • Novartis Investigative Site
    Mineola, New York 11501, United States
  • Novartis Investigative Site
    Darlinghurst, New South Wales 2010, Australia
  • Novartis Investigative Site
    Leuven, 3000, Belgium
  • Novartis Investigative Site
    Hannover, 30625, Germany
  • Novartis Investigative Site
    Roma, RM 00161, Italy
  • Novartis Investigative Site
    Vilnius, LT-08661, Lithuania
  • Novartis Investigative Site
    London, NW3 2QG, United Kingdom
09

References and documents

Publications

  • Frost AE, Barst RJ, Hoeper MM, Chang HJ, Frantz RP, Fukumoto Y, Galie N, Hassoun PM, Klose H, Matsubara H, Morrell NW, Peacock AJ, Pfeifer M, Simonneau G, Tapson VF, Torres F, Dario Vizza C, Lawrence D, Yang W, Felser JM, Quinn DA, Ghofrani HA. Long-term safety and efficacy of imatinib in pulmonary arterial hypertension. J Heart Lung Transplant. 2015 Nov;34(11):1366-75. doi: 10.1016/j.healun.2015.05.025. Epub 2015 Jun 11. PubMed 26210752 ↗
  • Hoeper MM, Barst RJ, Bourge RC, Feldman J, Frost AE, Galie N, Gomez-Sanchez MA, Grimminger F, Grunig E, Hassoun PM, Morrell NW, Peacock AJ, Satoh T, Simonneau G, Tapson VF, Torres F, Lawrence D, Quinn DA, Ghofrani HA. Imatinib mesylate as add-on therapy for pulmonary arterial hypertension: results of the randomized IMPRES study. Circulation. 2013 Mar 12;127(10):1128-38. doi: 10.1161/CIRCULATIONAHA.112.000765. Epub 2013 Feb 12. PubMed 23403476 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jun 2011, a primary completion of Mar 2014 and a completion of Mar 2014. It does not say whether these dates are actual or estimated.

Results were first posted in Jul 2015, 1 year 4 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 11, 2011
First posted
Jul 12, 2011
Start
Jun 2011
Primary completionActual
Mar 2014
CompletionActual
Mar 2014
Results first posted
Jul 13, 2015
Last update
Aug 10, 2015
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 10, 2015, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01392495
Responsible party
Sponsor
First posted
Jul 12, 2011
Start date
Jun 2011
Primary completion
Mar 2014
Completion
Mar 2014
Results posted
Jul 13, 2015
Last update
Aug 10, 2015

Study contacts

Novartis Pharmaceuticals
study director · Novartis Pharmaceuticals

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Jul 2015. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Imatinib

Start the discussion